The Latest Breaking News from Matthew Kacsmaryk

The ruling preserves broad access to mifepristone, while litigation continues over the pill’s approval for US use.

The Supreme Court weighs in on a case involving a drug commonly used for abortions that the FDA first approved in 2000.

The US Supreme Court is considering whether to uphold restrictions to the pill used in more than half of US abortions.

The US Supreme Court has ruled on a challenge to mifepristone pills, the most common method in the US, which was brought by anti-abortion campaigners in the first abortion controversy to reach the nation's highest court since its conservative majority overturned Roe v. Wade

The judge who blocked the FDA’s authorisation of mifepristone says he did not recall the interivew

The Supreme Court is facing a self-imposed Friday night deadline to decide whether women’s access to a widely used abortion pill will stay unchanged until a legal challenge to its Food and Drug Administration approval is resolved

The Supreme Court has given itself until midnight Friday to make an “emergency” decision on access to mifepristone, a drug used in half of all U.S. abortions. Whatever the outcome, it’s just a preliminary round in the battle over U.S. District Court Judge Matthew Kacsmaryk’s ruling earlier this month to…

The Supreme Court initially gave itself a deadline of Wednesday to decide whether women seeking access to a widely used abortion pill would face more restrictions while a court case plays out

Abortion opponents urged the U.S. Supreme Court to allow new restrictions on a widely used pill to end pregnancy, presenting the justices with a stark choice on one of the country’s most divisive issues.

WASHINGTON – Appellate Judge James Ho of Dallas, a former law clerk to Clarence Thomas, defended the justice’s honor Tuesday, rejecting ethics allegations involving lavish trips provided by real estate magnate Harlan Crow.

WASHINGTON – Sen. John Cornyn, R-Texas, said Tuesday he’s satisfied an Amarillo judge who tried to halt distribution of an FDA-approved abortion drug did not mislead the Senate by removing his name from an article bashing Obama administration efforts to protect those seeking abortions.